NEW YORK, June 12, 2017 /PRNewswire/ --
DailyStockTracker.com has issued research reports on CEL-SCI
Corp. (NYSEMKT: CVM), Amicus Therapeutics Inc. (NASDAQ: FOLD),
Galena Biopharma Inc. (NASDAQ: GALE), and Cleveland BioLabs Inc.
(NASDAQ: CBLI). According to a report on Seeking Alpha, the Biotech
sector, as represented by the NASDAQ Biotechnology Index ETF,
remains bound in a range between 280 and 300 level as it has been
for nearly three months. However, the trading range has tightened,
as the lower bound has risen from the 240 level in 2016. Daily
Stock Tracker published free research reports on these stocks today
at:
http://dailystocktracker.com/register/
CEL-SCI
Vienna, Virginia headquartered
CEL-SCI Corp.'s stock jumped 5.32%, finishing last Friday's trading
session at $0.10. A total volume of
4.16 million shares was traded, which was above their three months
average volume of 3.92 million shares. The Company's shares have
gained 6.60% over the previous three months and 56.25% since the
start of this year. The stock is trading above its 50-day moving
average by 7.54%. Additionally, shares of CEL-SCI, which engages in
the research and development of drugs and vaccines, have a Relative
Strength Index (RSI) of 55.75.
On June 08th, 2017,
CEL-SCI announced the publication of data from rheumatoid arthritis
studies in Vaccine, a leading peer-reviewed journal for
researchers interested in vaccines and vaccination. The paper is
titled "An epitope-specific DerG-PG70 LEAPS vaccine modulates T
cell responses and suppresses arthritis progression in two related
murine models of rheumatoid arthritis". See our free and
comprehensive research report on CVM at:
http://dailystocktracker.com/registration/?symbol=CVM
Amicus Therapeutics
Shares in Cranbury, New Jersey
headquartered Amicus Therapeutics Inc. ended at $8.46, down 1.97% from the last trading session.
The stock recorded a trading volume of 1.78 million shares. The
Company's shares have advanced 23.32% in the past month, 12.05%
over the previous three months, and 70.22% since the start of this
year. The stock is trading 12.20% and 22.20% above its 50-day and
200-day moving averages, respectively. Moreover, shares of Amicus
Therapeutics, which engages in the discovery, development, and
commercialization of medicines for various rare and orphan
diseases, have an RSI of 61.01.
On June 07th, 2017,
Amicus Therapeutics announced that John F.
Crowley, Chairman and CEO, will participate in a corporate
overview and fireside chat at the upcoming Goldman Sachs
38th Annual Global Healthcare Conference on Thursday, June 15th, 2017, at
10:40 a.m. PT in Rancho Palos Verdes, CA. A webcast of the
presentation can be accessed under the Investors section of the
Company's corporate website. FOLD free research report is just
a click away at:
http://dailystocktracker.com/registration/?symbol=FOLD
Galena Biopharma
On Friday, shares in San Ramon,
California-based Galena Biopharma Inc. recorded a trading
volume of 478,490 shares. The stock rose 0.34%, closing the day at
$0.56. The Company's shares are
trading 5.23% below their 50-day moving average. Additionally,
shares of Galena Biopharma, which develops hematology and oncology
therapeutics that address unmet medical needs, have an RSI of
44.51. Sign up for your complimentary report on GALE at:
http://dailystocktracker.com/registration/?symbol=GALE
Cleveland BioLabs
At the close of trading on Friday, shares in Buffalo, New York headquartered Cleveland
BioLabs Inc. recorded a trading volume of 65,306 shares. The stock
finished the session 1.40% lower at $3.51. The Company's shares have gained 4.46% in
the past month, 115.34% in the previous three months, and 147.18%
since the start of this year. The stock is trading above its 50-day
and 200-day moving averages by 11.29% and 73.31%, respectively.
Furthermore, shares of Cleveland BioLabs, which develops novel
approaches to activate the immune system and address various
medical needs in the US and the Russian
Federation, have an RSI of 52.50.
On May 15th, 2017,
Cleveland BioLabs reported financial results for Q1 ended
March 31st, 2017. Net loss
for Q1 2017 was $(1.7) million,
excluding minority interests, compared to a net loss of
$(0.7) million for Q1 2016. The
Company had $13.1 million in cash,
cash equivalents, and short-term investments, as of March 31st, 2017. Register for free on
DailyStockTracker.com and download the latest research report on
CBLI at:
http://dailystocktracker.com/registration/?symbol=CBLI
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. DST has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
DST has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email contact@dailystocktracker.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by DST. DST is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. DST, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, DST, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither DST nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA